Statement: Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.
Primary_evidence: Adverse Events 1:   Total: 5/11 (45.45%)   Diabetes insipidus  [1]1/11 (9.09%)   Nausea 0/11 (0.00%)   Ileus 1/11 (9.09%)   Dehydration 1/11 (9.09%)   Vomiting 0/11 (0.00%)   Pain NOS  [2]2/11 (18.18%)   Pain - abdomen 0/11 (0.00%)   Fracture  [3]0/11 (0.00%)   Progressive Disease 1/11 (9.09%)   CNS Ischemia 1/11 (9.09%)   Respiratory Failure 0/11 (0.00%)   Hypoxia 1/11 (9.09%) Adverse Events 2:   Total: 8/21 (38.10%)   Diabetes insipidus  [1]0/21 (0.00%)   Nausea 1/21 (4.76%)   Ileus 0/21 (0.00%)   Dehydration 1/21 (4.76%)   Vomiting 1/21 (4.76%)   Pain NOS  [2]0/21 (0.00%)   Pain - abdomen 1/21 (4.76%)   Fracture  [3]1/21 (4.76%)   Progressive Disease 1/21 (4.76%)   CNS Ischemia 1/21 (4.76%)   Respiratory Failure 1/21 (4.76%)   Hypoxia 1/21 (4.76%)